ストックスクリーナーアプリを入手
0.1897
6.64%
-0.0135
アフターアワーズ：
.18
-0.0097
-5.11%
前日終値:
$0.2032
開ける：
$0.2035
24時間の取引高:
800.84K
Relative Volume:
1.47
時価総額：
$12.86M
収益：
$9.14M
当期純損益:
$-124.31M
株価収益率:
-0.1982
EPS:
-0.9573
ネットキャッシュフロー:
$-125.43M
1週間 パフォーマンス:
-9.75%
1か月 パフォーマンス:
-44.21%
6か月 パフォーマンス:
-84.94%
1年 パフォーマンス:
-91.79%
1日の値動き範囲:
$0.18
$0.2035
1週間の範囲:
$0.18
$0.227
52週間の値動き範囲:
$0.18
$2.4292
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Compare TCRX vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.1897 | 12.86M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
517.49 | 131.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.67 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.85 | 79.39B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
869.33 | 54.67B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.87 | 41.95B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-08 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-11-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | 開始されました | BTIG Research | Buy |
| 2024-05-13 | 開始されました | Needham | Buy |
| 2023-06-22 | 開始されました | Wedbush | Outperform |
Tscan Therapeutics Inc (TCRX) 最新ニュース
Form PRE 14A Tscan Therapeutics Inc For: 16 October By Investing.com - Investing.com Nigeria
A CEO receives stock with 75% conditionally vesting on a trial milestone or in 2030 at TScan Therapeutics (TCRX). - Stock Titan
CFO and medical chief will leave by November 1, 2026, at TScan Therapeutics (TCRX). - Stock Titan
Three parties report shared voting power over more than 5% of TScan Therapeutics (TCRX). - Stock Titan
Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis - Kalkine
TScan Therapeutics announces retention program for key executives - Investing.com
Form 8K Tscan Therapeutics Inc For: 11 September By Investing.com - Investing.com Australia
TScan Therapeutics Launches Executive Retention Incentive Program - TipRanks
TScan Therapeutics announces retention program for key executives By Investing.com - Investing.com India
Form 8K Tscan Therapeutics Inc For: 11 September By Investing.com - Investing.com India
TScan Therapeutics announces retention program for key executives By Investing.com - Investing.com UK
TScan Therapeutics announces retention program for key executives - Investing.com
TScan Therapeutics grants retention awards to CEO Gavin MacBeath and CLO Zoran Zdraveski - TradingView
New milestone-tied pay plan for TScan Therapeutics (TCRX) leaders - Stock Titan
Form 8K Tscan Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa
TSCAN THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TARGET PRICE TO $1 FROM $7 - webull.com
H.C. Wainwright Downgrades TScan Therapeutics(TCRX.US) to Hold Rating, Cuts Target Price to $1 - Moomoo
H.C. Wainwright downgrades Tscan stock rating on restructuring - Investing.com
H.C. Wainwright downgrades Tscan stock rating on restructuring By Investing.com - Investing.com Canada
H.C. Wainwright downgrades Tscan stock rating on restructuring - Investing.com India
H.C. Wainwright downgrades Tscan stock rating on restructuring By Investing.com - Investing.com UK
H.C. Wainwright downgrades Tscan stock rating on restructuring By Investing.com - Investing.com South Africa
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme StudySlideshow (NASDAQ:TCRX) 2026-09-04 - Seeking Alpha
TScan Therapeutics Cuts 75% of Staff, Pivots to In Vivo TCR-T for Solid Tumors - BioPharm International
TCRX Downgraded by Wedbush -- Price Target Lowered to $1.00 - GuruFocus
Tscan prioritizes in vivo solid tumor program - BioWorld News
TScan Therapeutics IncExpects to Incur Abo - Moomoo
TScan Therapeutics sheds majority of staff, pauses Phase 3 trial amid funding shortfall - The Business Journals
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com Nigeria
Crude Oil Moves Higher; US Factory Orders Rise In July - Benzinga
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction - Benzinga
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com South Africa
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com Canada
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com UK
Why is TScan Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
Why is TScan Therapeutics stock collapsing today? By Investing.com - Investing.com UK
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program - Yahoo Finance
TScan Therapeutics Restructures to Focus on Solid Tumors - TipRanks
TScan Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors - GlobeNewswire
Why is TScan Therapeutics stock collapsing today? - Investing.com
TCRX 8-K & SEC Filings - Yahoo Finance Australia
TScan Therapeutics highlights push into in vivo-engineered TCR-T cell therapy for solid tumors in corporate presentation - Bitget
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Barchart.com
TScan Therapeutics (TCRX) Holds at $0.75 as Biotech Stock Defends Key SupportSell Signal Alerts - dars.gov.et
TScan Therapeutics (TCRX) Holds at $0.75 as Biotech Stock Defends Key SupportWave Extension - vinanet.vn
Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership? - Yahoo Finance
Is Amgen (AMGN) Refocusing Its R&D Portfolio With The Exit From TScan’s Crohn’s Deal? - simplywall.st
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy - Fierce Biotech
Tscan Therapeutics Inc (TCRX) 財務データ
収益
当期純利益
現金流量
EPS
Tscan Therapeutics Inc (TCRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
2.13%
1.86%
大文字化:
|
ボリューム (24 時間):